Asset profile
APG-2575(Lisaftoclax )
Small molecule
Evidence outlook · registrational
Acute Myeloid Leukemia: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-05-25.
Also in development:Multiple Myeloma · Phase 1/2Systemic Lupus Erythematosus · Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
182 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 171 same-indication; 41 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| APG-2575(Lisaftoclax ): this drug | Phase 3 | Small molecule | BCL-2 | ||
| Venetoclax | Approved | Small molecule | BCL-2 | ||
| BGB-11417 | Phase 3 | — | BCL-2 | ||
| ICP-248 | Phase 2/3 | — | BCL-2 | ||
| FCN-338 | Phase 2 | Small molecule | BCL-2 | ||
| Surzetoclax | Phase 1/2 | Small molecule | BCL-2 | ||
| TGRX-814 | Phase 1/2 | — | BCL-2 | ||
| FXS0683 | Phase 1 | Biologic (subtype unspecified) | BCL-2 | ||
| Lonitoclax | Phase 1 | Small molecule | BCL-2 | ||
| LOXO-338 | Phase 1 | Small molecule | BCL-2 | ||
| ZE 50-0134 | Phase 1 | — | BCL-2 | ||
| BGB-21447 | Phase 1 | Small molecule | BCL-2 | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA |
…and 167 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
2027 (6)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
September 2027 (1)
What to watch
2028 (10)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
May 2028 (2)
June 2028 (1)
What to watch
September 2028 (3)
What to watch
What to watch
What to watch
October 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (4)
February 2029 (1)
What to watch
June 2029 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.